Immuneering Corporation reported its financial results for the second quarter ended June 30, 2025, on August 13, 2025. The company held $26.4 million in cash and cash equivalents as of June 30, 2025, compared with $36.1 million at the end of 2024. Research and Development (R&D) expenses for Q2 2025 were $10.5 million, a slight decrease from $10.7 million in Q2 2024, primarily due to reduced spend on preclinical and IMM-6-415 programs, offset by higher costs for atebimetinib.
The net loss attributable to common stockholders for the quarter was $14.4 million, or $0.40 per share, compared to $14.1 million, or $0.47 per share, for Q2 2024. The company reiterated the exceptional 94% overall survival (OS) observed at 6 months in its ongoing Phase 2a trial of atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34). Immuneering now plans to share updated OS and PFS data from these patients in Q3 2025, earlier than previously guided.
Immuneering also highlighted the newly issued U.S. composition of matter patent for atebimetinib, which is expected to provide exclusivity into 2042. The company has submitted a request for an End of Phase 2 meeting to the FDA, with a pivotal trial expected to initiate in 2026. Despite projecting a cash runway into 2026, management issued a "going concern" warning, indicating that current funds are not sufficient for a full year from the financial statement issuance date.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.